Prevalence, Predictors, and Successful Treatment Outcomes of Xpert MTB/RIF-identified Rifampicin-resistant Tuberculosis in Post-conflict Eastern Democratic Republic of the Congo, 2012–2017: A Retrospective Province-Wide Cohort Study

André N. H. Bulabula,1,2 Jenna A. Nelson,3 Eric M. Musafiri,4 Rhoderick Machekeano,5 Nadia A. Sam-Agudu,6,7 Andreas H. Diacon,8 Maunank Shah,9 Jacob Creswell,10 Grant Theron,11 Robin M. Warren,11 Karen R. Jacobson,12 Jean-Paul Chirambiza,4 Dieudonné Kalumuna,4 Bertin C. Bisimwa,13
1Department of Global Health, Division of Health Systems and Public Health, Unit for Infection Prevention and Control, Faculty of Medicine and Health Sciences, Stellenbosch University; 2Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pennsylvania; 3National Tuberculosis Program, Provincial Leprosy and Tuberculosis Coordination, South Kivu Branch, Bukavu, Democratic Republic of the Congo; 4Department of Global Health, Center for Evidence-Based Health Care, Biostatistics Unit, Faculty of Medicine and Health Sciences, Cape Town, South Africa; 5International Research Center of Excellence and Pediatric and Adolescent Human Immunodeficiency Virus Unit, Institute of Human Virology Nigeria, Abuja; 6Division of Epidemiology and Prevention, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, 7Division of Medical Physiology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; 8Center for Tuberculosis Research & Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, Maryland; 9Stop TB Partnership, TB REACH Initiative, Geneva, Switzerland; 10South African Department of Science and Technology and the National Research Foundation, Centre of Excellence for Biomedical Tuberculosis Research and South African Medical Research Council Centre for Tuberculosis Research and South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; 11Department of Medicine, Division of Infectious Diseases, Boston University School of Medicine, Massachusetts; 12Biomedical Laboratory Professor A. Z. Lurhuma, Mycobacterium South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; 13Department of Internal Medicine, Catholic University of Bukavu, and 14The Union Against Tuberculosis and Lung Diseases, Challenge Tuberculosis Initiative, Bukavu, Democratic Republic of the Congo; 15Center for Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, The Academic Medical Center, The Netherlands; 16Department of Medicine, University Hospital of Kinshasa, Democratic Republic of the Congo; 17Department of Medicine and Center for Infectious Diseases, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa; 18Departments of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; 19Department of Global Health, Division of Health Systems and Public Health, Unit for Infection Prevention and Control, Faculty of Medicine and Health Sciences, Stellenbosch University; 20Departments of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; 21International Centre for Advanced Research and Training, Panzi, Bukavu, Democratic Republic of the Congo.

Background. Multidrug-resistant tuberculosis (MDR-TB) jeopardizes global TB control. The prevalence and predictors of Rifampicin-resistant (RR) TB, a proxy for MDR-TB, and the treatment outcomes with standard and shortened regimens have not been assessed in post-conflict regions, such as the South Kivu province in the eastern Democratic Republic of the Congo (DRC). We aimed to fill this knowledge gap and to inform the DRC National TB Program.

Methods. A retrospective cohort study of adults and children evaluated for pulmonary TB by sputum smear microscopy and Xpert MTB/RIF (Xpert) from February 2012 to June 2017. Multivariable logistic regression, Kaplan–Meier estimates, and multivariable Cox regression were used to assess independent predictors of RR-TB and treatment failure/death.

Results. Of 1535 patients Xpert-positive for TB, 11% had RR-TB. Independent predictors of RR-TB were a positive sputum smear (adjusted odds ratio [aOR] 2.42, 95% confidence interval [CI] 1.63–3.59), retreatment of TB (aOR 4.92, 95% CI 2.31–10.45), and one or more prior TB episodes (aOR 1.77 per episode, 95% CI 1.01–3.10). Over 45% of RR-TB patients had no prior TB history or treatment. The median time from Xpert diagnosis to RR-TB treatment initiation was 12 days (interquartile range 3–60.2). Cures were achieved in 30/36 (83%) and 84/114 (74%) of patients on 9- vs 20/24-month MDR-TB regimens, respectively (P = .06). Predictors of treatment failure/death were the absence of directly observed therapy (DOT; adjusted hazard ratio [aHR] 2.77, 95% CI 1.2–6.66) and any serious adverse drug event (aHR 4.28, 95% CI 1.88–9.71).

Conclusions. Favorable RR-TB cure rates are achievable in this post-conflict setting with a high RR-TB prevalence. An expanded Xpert scale-up; the prompt initiation of shorter, safer, highly effective MDR-TB regimens; and treatment adherence support are critically needed to optimize outcomes.

Keywords. multidrug-resistant TB; prevalence; predictors; treatment outcomes; eastern DR Congo.

1278 • CID 2019:69 (15 October) • Bulabula et al
Multidrug-resistant tuberculosis (MDR-TB), defined as resistance to rifampicin and isoniazid, poses a global threat to TB control efforts [1, 2]. In contrast to downward trends in 30 high-burden countries, the Democratic Republic of the Congo (DRC) has had persistently high TB incidences and mortality rates [2]. In 2017, among the 81 million people in DRC, there was an estimated TB incidence of 322/100,000 and an estimated 60,000 TB-related deaths [2]. Estimated DRC MDR-TB rates were 2.2% among new cases and 9.7% in retreatment cases [2]. Limited laboratory infrastructure for both MTB cultures and drug susceptibility testing (DST) makes the determination of the actual MDR-TB burden and of treatment outcomes challenging [3, 4].

The second Congo war, in the aftermath of the 1994 Rwandan genocide, caused a massive disruption of health-care services in the eastern DRC [5]. In 2012, South Kivu was the first province of eastern DRC to roll out the Xpert MTB/RIF assay (Xpert; Cepheid, Sunnyvale, CA), a rapid genotypic assay for rifampicin susceptibility via $rpoB$ mutation detection [6–8]. Laboratory capacities for Xpert were established at 10 TB diagnostic and treatment centres (CSDTs) in South Kivu province through the Stop TB Partnership’s TB REACH initiative [9]. Creswell et al reported a 5.3% prevalence of Xpert-diagnosed rifampicin-resistant TB (RR-TB) in South Kivu [10], compared to a 9.6% prevalence among smear-negative TB cases in the capital city Kinshasa, as reported by Mbonze et al [11]. Both studies focused on strategies to improve finding TB cases and on early Xpert user experiences, but did not document the risk factors for, or clinical outcomes of, RR-TB treatment.

We aimed to assess the prevalence and predictors of RR-TB, as well as treatment outcomes, to inform the strategic plan of the DRC National TB Program (NTP) and guide models development to improve MDR-TB care in low- and middle-income countries (LMICs).

**METHODS**

**Study Design, Setting, and Population**

We performed a secondary analysis of data collected routinely from adults and children and evaluated for suspected pulmonary TB at 10 Xpert-equipped CSDTs serving 34 health zones of the South Kivu province from 1 February 2012 to 30 June 2017 (Figure 1). While described as post-conflict, the eastern DRC is still considered unstable, given the continued presence of multiple active militias [5]. TB cases were found and identified either passively (by referral) or actively (via symptom screening by community health workers [CHWs]). Ziehl-Neelsen sputum smear microscopy for acid-fast bacilli (AFB) and Xpert were performed on different sputum samples. Human immunodeficiency virus (HIV) status was not documented systematically, due to out-of-stock test kits.

**Treatment Regimens and Monitoring**

Previously untreated, rifampicin-susceptible TB (RS-TB) patients received the standard, 6-month, first-line drug regimen, including 2 months of rifampicin ($R$), isoniazid ($H$), pyrazinamide ($Z$), and ethambutol ($E$), followed by 4 months of $R$ and $H$ ($2RHZ/4RH$). Retreatment cases after failure, relapse, or loss to follow-up (LTFU) received an 8-month regimen, including streptomycin ($S$) for the first 2 months ($2SRHZ/1RHZE/5RHE$) [11]. As recommended by World Health Organization (WHO) for reporting purposes, we considered RR-TB as a proxy for MDR-TB, because rifampicin mono-resistant TB has been considered relatively rare [2]. MDR-TB regimens included the standard, 9-month, shorter regimen with moxifloxacin ($Mfx$), clofazimine ($Cfz$), $E$, and $Z$ throughout, supplemented by kanamycin ($Km$), prothionamide ($Pto$), and high-dose isoniazid ($Hh$) during a 4-month intensive phase ($4KmMfxPtoCfzZHhE/5MfxCfzZE$) [12]. This regimen became available to our study cohort in 2016. A GenoType MTBDRsl (Hain LifeScience GmbH, Nehren, Germany) assay [11] was performed at the Biomedical Laboratory Professor A. Z. Lurhuma, Université Catholique de Bukavu, Bukavu (Figure 1), to exclude resistance to $Mfx$ or $Km$, as per 2016 WHO guidelines on use of the shorter MDR-TB regimen [13]. The individualized (conventional) 20- or 24-month MDR-TB
regimen included ofloxacin (Ofx) or levofloxacin (Lfx) and cycloserine (Cs) throughout (6KmOfxPtoCsEZ/180OfxPtoCsEZ or 6KmLfxPtoCsEZ/14LfxPtoCsEZ, respectively) and was for RR-TB patients recruited before 2016 or not eligible for the 9-month regimen.

Patient responses to MDR-TB treatment were monitored monthly during the intensive phase and every 2 months during the continuation phase, with a sputum smear for AFB (if positive at baseline) and/or mycobacterial culture most frequently done on traditional Löwenstein–Jensen solid media. The BACTEC Mycobacteria Growth Indicator Tube liquid cultures (Becton Dickinson, Sparks, MD) were performed only occasionally, due to their relatively high cost. Monitoring for drug toxicity included baseline and follow-up clinical assessments; electrolyte, liver (if symptomatic), renal, and thyroid function tests; and visual acuity and audiometric assessments, per DRC NTP guidelines [12, 14]. MDR-TB patients were not hospitalized unless medically indicated. Directly observed therapy (DOT) was conducted by a nurse at the nearest CSDT, either daily during the intensive phase or weekly during the continuation phase; on the remaining days of the week, home-based DOT was performed by a trained CHW or an assigned family member. Of note, patients were provided incentives—food parcels, for nutritional support, and transportation subsidies (US $30/per month)—to facilitate their daily or weekly attendance at CSDTs for DOT [12].

Treatment Outcomes Definitions

WHO definitions were used for MDR-TB treatment outcomes [13]. Cured indicates a patient who has completed treatment and has at least 3 consecutive, negative sputum smears for AFB or MTB cultures, with at least 30 days in between. Treatment completion indicates a patient who has completed treatment, but does not have bacteriologic confirmation. Death indicates a patient who dies for any reason during the course of treatment. Failure indicates a patient with (1) a positive sputum smear for AFB or MTB culture at 5 months or later after initiation of MDR-TB regimen, or (2) a bacteriological reversion to positive after conversion. Treatment success includes patients with cures or treatment completion, while unsuccessful treatment includes patients who died, failed treatment, or relapsed. LTFU refers to a patient lost to follow-up for 2 or more consecutive months. Of note, the WHO benchmarks for treatment successes and cures among TB patients, regardless of their drug resistance statuses, are ≥90% and >80%, respectively [2].

Statistical Analysis

Data were summarized using proportions and medians (interquartile range [IQR]) for categorical and continuous variables, respectively. Chi-square tests and Wilcoxon rank sum tests were applied for tests of association, where appropriate. Using logistic regression models, we estimated the unadjusted association between individual, baseline characteristics and RR-TB. We estimated adjusted associations by including all baseline covariates a priori in a multivariate model. Starting with a full model, we then used a backward elimination procedure, excluding predictor variables with a P value < .1, and compared the estimated reduced model adjusted odds ratios (aOR) and associated 95% confidence intervals (CIs) to the full multivariate model estimates. The final model was based on variables with statistical significance in both the full and reduced models, plus variables known to have clinical significance. Patients who were LTFU were censored at the date of last appointment. Treatment failure was summarized using Kaplan–Meier estimates, and TB treatment survival was compared between regimens using log-rank tests. Univariable and multivariable Cox regression modelling identified those predictors independently associated with the hazard of treatment success or failure. Adjusted hazard ratios (aHR) and their associated 95% CIs were calculated to summarize the strength of associations between patient characteristics and treatment failure. For each baseline characteristic, we evaluated the proportional hazards assumption by checking for parallel lines in plots of −log{−log(survival)} versus log(time) for each category. For the final multivariate models, we performed a universal test of proportional hazards based on Schoenfeld residuals. All P values that we report are exact and two-tailed; a value less than .05 was considered statistically significant. Stata software version 13.1 (Stata, College Station, TX) was used for all statistical analyses.

Ethics Approvals

This study was approved by the Health Research Ethics Committees of Stellenbosch University, Cape Town, South Africa (reference number S15/03/059) and the Université Catholique de Bukavu’s Referral Provincial Hospital, Bukavu, South Kivu Province, DRC (reference number 25.042/946/Staff/LK/HPGRB/BKV/014).

RESULTS

Baseline Demographics and Clinical Characteristics

Figure 2 displays the patient flow for all 10 CSDTs during the study period: 16,488 patients with presumptive pulmonary TB were screened by Xpert, capturing over 90% of those diagnosed with TB during the study period from these CSDTs. Their age range was 1–98 years, their median age was 35 years (IQR 24–52), and 55.2% were male. Ultimately, 1,535 (9.3%) patients were confirmed by Xpert or culture to have TB. The median time from a positive Xpert result to TB treatment initiation was significantly longer for RR-TB vs RS-TB patients (12.0 [IQR 3.0–60.2] days vs. 1.0 [IQR 0.0–4.4] days, respectively; P < .001; Table 1).

Prevalence and Predictors of Rifampicin Resistance Tuberculosis

Of the 1,535 Xpert MTB-positive patients, 170 (11.1%, 95% CI 9.5–12.8) had RR-TB; 46.5% of those with RR-TB had no prior TB episode. The prevalence of RR-TB was lowest among new TB cases (5.6%), but for previous treatment failure, relapse, or...
LTFU cases, the prevalences of RR-TB were 47%, 38.1%, and 42.9%, respectively (Table 1). RR-TB was significantly more likely among retreatment vs new cases (aOR 4.92, 95% CI 2.31–10.45) and positive sputum smear cases (aOR 2.23, 95% CI 1.49–3.32). For each prior TB episode, the risk of RR-TB was increased nearly 2-fold. Age, sex, and HIV status were not associated with RR-TB (Table 2).

**Treatment Outcomes**

TB treatment was initiated in 1503 of 1535 (98%) patients. When 6- or 8-month standard regimens were administered, 1028 of 1184 (87%) RS-TB patients were treated successfully. Of the 170 patients with RR-TB, 68 (40%), 57 (34%), and 36 (21%) were treated with the 24-, 20-, and 9-month MDR-TB regimens, respectively; 9 (5%) were LTFU or dead before treatment initiation. The success rate of the 9-month regimen was 30/36 (83%). The 20/24-month regimen achieved success and cures in 90/114 (79%) and 84/114 (74%) of evaluable patients, respectively (Figure 3). Treatment successes ($P = .64$) or cures ($P = .06$) following treatment for RR-TB did not differ significantly between the 9- or 20/24-month regimens. Of note, there was no $mfx$ and $km$ resistance documented (0/36, 0.0%) for RR-TB patients screened by GenoType MTBDRsl assay for the shorter MDR-TB regimens.

Serious adverse events (SAEs; grade III-IV) were more common among RR- vs RS-TB patients (16.2% vs 0.7%, respectively; $P < .001$). Among 159 RR-TB patients, SAEs were reported as follows: ototoxicity ($n = 13$, 8%), renal failure ($n = 4$, 2.4%), hepatitis ($n = 4$, 2.4%), anaemia ($n = 2$, 1.2%), and optic neuritis ($n = 1$, 0.5%). Having any SAE was independently associated with a more than 4-fold increase in the hazard of treatment failure (Table 3). There was a significant difference in the time to either death or treatment failure, relative to the initiation of treatment by DOT (aHR 3.42, 95% CI 1.34–8.72) and any SAE (aHR 4.81, 95% CI 2.04–11.30; Figures 4A and B), but not when comparing by HIV status (aHR 2.83, 95% CI 0.77–10.39; Figure 4C) or by 9- vs 20/24-month MDR-TB regimens (aHR 1.02, 95% CI 0.41–2.56; Figure 4D).

**DISCUSSION**

We observed a high prevalence (11.1%) of RR-TB among nearly 1600 adults and children with Xpert-positive MTB in the South Kivu province. Independent predictors of RR-TB were sputum smear positivity and retreatment TB, and 46.5% of RR-TB patients had no prior TB episode. High proportions of RR-TB patients on 9- (83%) and 20/24- month (74%) MDR-TB regimens were cured ($P = .06$). Independent predictors of treatment failure/death while on an RR-TB regimen were the lack of DOT and the occurrence of any SAE.

Our data are consistent with those of Mbonze et al, who found a high prevalence (9.6%) of RR-TB among 991 samples from Kinshasa [11]. Creswell et al, however, in their TB REACH report analyzing data from three South Kivu sites, found that...
only 5.3% (n = 567) of samples that tested positive by Xpert were RR-TB [10]. Factors accounting for the differences between our study and that of Creswell include our larger sample size and coverage area, the longer observation time, and the greater number of retreatment cases tested.

Patients with RR-TB were more likely to have positive sputum smears for AFB and to be retreatment TB cases. The latter situation could be a consequence of the prior lack of DST, due to limited laboratory capacities and leading to empiric RS-TB treatment. Inadequate treatment leads to progressive TB and the presence of persistently sputum smear-positive individuals in the community, with increased TB transmission as strains have more opportunities to mitigate fitness costs through compensatory mutations [15, 16]. We also found that even one prior TB treatment episode was associated with a roughly 80% increase in the odds of acquiring RR-TB, which is in agreement with several other reports from LMICs [17–19].

Importantly, we documented the evidence for transmitted RR-TB, since over 40% of those with RR-TB had no prior TB episode (Table 1). This is in line with published empiric and modelling data suggesting that, in high TB burden settings, many cases of RR-TB result from the transmission of drug-resistant strains of TB, rather than from acquired resistance [2, 20, 21]. Therefore, improving the diagnosis, prevention, and treatment strategies of both RS- and RR-TB cases, including access to genotypic DST and shorter regimens, is critical [22].

Of concern, the median time from a positive Xpert result to treatment initiation was delayed to nearly 60 days for more than 25% of patients with RR-TB, due to out-of-stock drugs and supply chain issues of second-line drugs (SLDs), as they need to be transported from the capital city of Kinshasa to the remote CSDTs. To maximally benefit from Xpert testing, these important logistical and structural challenges must be addressed by the DRC’s NTP and stakeholders.

We did not find any significant association between HIV infection and RR-TB prevalence, treatment failure, or mortality; however, our study had limited statistical power for such associations, most likely due to the low HIV prevalence (<5%) in the South Kivu province and/or the 18.8% of RR-TB patients not tested for HIV. While there are conflicting reports about

### Table 1. Baseline Demographic and Clinical Characteristics by Xpert MTB/RIF Assay Result

| Overall | TB Negative | TB Positive | RS-TB | RR-TB |
|---------|-------------|-------------|-------|-------|
| Sample size, n (%) | 16,357 (100)* | 14,822 (90.6) | 1,535 (9.4) | 1,365 (88.9)* | 170 (11.0)* |
| Median age, years (IQR) | 36 (24–52) | 37 (24–52) | 35 (26–45) | 35 (26–45) | 35 (27–44) |
| Age <20 years | 2,648 (16.2%) | 2,481 (16.7%) | 167 (10.9%) | 153 (11.2%) | 14 (8.2%) |
| Age ≥20 years | 13,709 (83.8%) | 12,341 (83.3%) | 1,368 (89.1%) | 1,212 (88.8%) | 156 (91.8%) |
| Male sex, n (%) | 9,029 (55.2) | 8,028 (54.2) | 1,001 (65.2) | 886 (64.9) | 115 (67.6) |
| HIV status, n (%) | | | | | |
| Negative | 994 (6.1) | 29 (0.2) | 965 (62.8) | 843 (61.7) | 122 (71.7) |
| Positive | 135 (0.8) | 28 (0.2) | 107 (6.9) | 91 (6.7) | 16 (9.4) |
| Unknown | 15,228 (93.1) | 14,765 (99.6) | 463 (30.1) | 431 (31.6) | 32 (18.8) |
| WHO HIV stage, n (%) | | | | | |
| Stage I–III | 95 (67.4) | 7 (0.5) | 88 (52.2) | 76 (53.5) | 12 (75.0) |
| Stage IV | 12 (8.9) | 0 (0.0) | 12 (7.1) | 8 (5.6) | 4 (25.0) |
| Missing data | 28 (20.7) | 21 (75.0) | 7 (4.5) | 7 (4.7) | 0 (0.0) |
| TB category, n (%) | | | | | |
| New cases | ... | ... | 1,289 (84.0) | 1,217 (89.0) | 72 (42.4) |
| Retreatment | ... | ... | 234 (15.2) | 136 (10.0) | 98 (57.6) |
| After failure | ... | ... | 66 (4.2) | 35 (2.6) | 31 (18.2) |
| After relapse | ... | ... | 105 (6.8) | 65 (4.8) | 40 (23.5) |
| After LTFU | ... | ... | 63 (4.1) | 36 (2.7) | 27 (15.9) |
| Missing data | ... | ... | 12 (0.8) | 12 (0.9) | 0 (0.0) |
| Prior TB Episode, n (%) | | | | | |
| 0 | ... | ... | 1,296 (84.4) | 1,217 (89.9) | 79 (46.5) |
| 1 | ... | ... | 185 (12.0) | 121 (8.9) | 64 (37.6) |
| ≥2 | ... | ... | 42 (2.7) | 15 (1.1) | 27 (15.8) |
| Missing data | ... | ... | 12 (0.8) | 12 (0.9) | 0 (0.0) |
| Median (IQR) days from Xpert MTB/RIF result to treatment | ... | ... | 1.6 (0–6.2) | 1.0 (0–4.4) | 12 (3–62.4) |
| Positive sputum smear microscopy for AFB, n (%) | 715 (4.5) | 92 (0.6)* | 623 (40.5) | 499 (36.6) | 124 (72.9) |

Abbreviations: AFB, acid-fast bacilli; HIV, human immunodeficiency virus; IQR, interquartile range; LTFU, lost to follow-up; MDR, multidrug resistant; RR, rifampicin resistant; RS, rifampicin susceptible; S, success; TB, tuberculosis; WHO, World Health Organization.

*aThis total excludes the indeterminate Xpert MTB/RIF assay results.

*bThis percentage uses TB-positive cases (n = 1535) as a denominator.

*cPossible contamination by non-tuberculous Mycobacteria.
associations between HIV and MDR-TB prevalence [23–25], the negative impact of HIV on MDR mortality is well established [26]. Indeed, in a meta-analysis including 2725 HIV-infected adults and children with MDR-TB, Isaakidis et al found that only 57% were treated successfully, and the mortality among HIV-infected adults was 4 times higher than that of HIV-negative populations (38% vs 11%), while mortality among children was twice as high (11.5% vs 6%) [26].

We documented similar programmatic treatment success with 9- and 20/24-month MDR-TB regimens. These results are in line with those reported from observational studies in Bangladesh and sub-Saharan Africa [27–33], as well as the interim results of the standardised treatment regimen of anti-TB drugs for patients with MDR-TB (STREAM) Stage 1 trial, which showed that both the shorter and longer MDR-TB regimens achieved success in roughly 80% of participants [34, 35]. The documented 0.0% MTB resistance to \textit{Mfx} and \textit{Km} in our setting may account, in part, for this favorable outcome. Also, our data, similar to those of others, show that SAEs are associated with unsuccessful MDR-TB outcomes [36].

In the STREAM Stage 2 trial, second-line injectable drugs were replaced by a fully oral, bedaquiline (BDQ)-containing regimen, one of the two new (along with delamanid [DLM]) potent MDR-TB drugs [37, 38] that are now being prescribed increasingly in LMICs following compassionate pilot access programs [39]. In August 2018, the WHO recommended that initiation of the shorter regimen be conditional to: (1) availability of DST, to exclude resistance to at least \textit{Mfx} and \textit{Km}, and (2) close

![Figure 3. Treatment outcomes, comparing patients with RS-TB treated with a 6/8-month standard TB treatment regimen to patients with RR-TB treated with a 9- or 20/24-month MDR-TB regimen. Abbreviations: Co, treatment completion without bacteriologic confirmation; Cu, cured or treatment completion with bacteriologic confirmation; L, lost to follow-up; MDR, multidrug resistant; RR, rifampicin resistant; RS, rifampicin susceptible; S, success; TB, tuberculosis; U, unsuccessful (failure or death).](image-url)
monitoring of the patient’s safety, as well as their treatment response [13, 35]. Switching non-responding patients (or those experiencing SAEs) to alternative SLDs and/or new regimens needs to be based on the new regrouping of MDR-TB drugs, ideally all oral, including BDQ or DLM [35].

Finally, we found that treatment under DOT was significantly associated with a decreased hazard of death/failure among RR-TB patients, as also reported in the meta-analysis by Ahuja et al [40]. However, it is likely that DOT is facilitated by socioeconomic incentives that, in turn, minimize LTFU and optimize patient outcomes, as also reported by Charles et al in post-earthquake Port-au-Prince, Haiti [41]. Of note, a meta-analysis by Richterman et al showed that patients receiving cash incentives during treatment for active RS-TB experienced improved clinical outcomes [42], but an assessment of the efficacy and cost-effectiveness of socioeconomic incentives for MDR-TB patients is needed.

Our data have important clinical/public health implications and can inform models of MDR-TB care in LMICs, including: (1) the scale-up of Xpert and genotype DST to identify earlier cases of MDR-TB among new and retreatment cases; (2) investments in socioeconomic incentives and training CHWs to deliver home-based DOT; (3) the integration of TB/HIV testing and treatment services; and (4) the need for household-based MDR-TB prevention strategies. However, confirmation of the impact of some of the above interventions will require prospective, interventional studies and cost-effectiveness analyses.

Our study has several strengths: (1) a detailed analysis of a large sample of Xpert-diagnosed TB cases in adults and children recruited from multiple TB diagnostic and treatment centers across the South Kivu province; (2) cohort data from a post-conflict setting, with multiple barriers to health care providing both feasibility data and MDR-TB treatment outcomes data relevant to TB clinicians and NTP implementers, as well

| Variable | N | Died or Failed, n (%) | Crude HR (95% CI) | P Value | Adjusted HR (95% CI) | P Value |
|----------|---|----------------------|-------------------|---------|----------------------|---------|
| Age, years | | | | | | |
| <20 | 13 | 3 (23.1) | 1.00 | ... | ... | ... |
| 20–24 | 18 | 6 (33.3) | 1.67 (.31–9.14) | .552 | ... | ... |
| 25–39 | 74 | 18 (24.3) | 1.41 (.32–6.17) | .647 | ... | ... |
| 40–59 | 44 | 9 (20.4) | .92 (.18–4.54) | .914 | ... | ... |
| >60+ | 10 | 3 (30.0) | 1.54 (.22–10.92) | .667 | ... | ... |
| Sex | | | | | | |
| Female | 50 | 17 (34.0) | 1.00 | ... | ... | ... |
| Male | 109 | 22 (20.1) | .53 (.26–1.11) | .091 | ... | ... |
| HIV Status | | | | | | |
| Negative | 117 | 25 (21.4) | 1.00 | ... | 1.00 | ... |
| Positive | 16 | 5 (31.2) | 1.191 (.65–5.62) | .239 | 2.83 (.77–10.39) | .116 |
| Unknown | 24 | 9 (37.5) | 1.56 (.62–3.92) | .340 | 0.74 (.23–2.40) | .622 |
| Sputum smear microscopy for AFB | | | | | | |
| Negative | 39 | 11 (28.2) | 1.00 | ... | ... | ... |
| Positive | 120 | 28 (23.3) | .87 (.38–1.97) | .748 | ... | ... |
| TB category | | | | | | |
| New cases | 64 | 18 (28.1) | 1.00 | ... | ... | ... |
| Re-treatment cases | 96 | 21 (22.1) | .58 (.28–1.22) | .152 | ... | ... |
| TB episode number | | | | | | |
| Per 1 prior episode of TB | 159 | 56 (36.7) | .67 (.39 – 1.15) | .143 | ... | ... |
| Days from result to treatment | 141 | 100 (99–100) | 1.00 | ... | .687 | ... |
| MDR-TB regimen | | | | | | |
| 20/24-month | 114 | 24 (21.1) | 1.00 | ... | ... | ... |
| 9-month | 36 | 6 (16.7) | 1.02 (.41–2.56) | .963 | ... | ... |
| DOT | | | | | | |
| No | 26 | 13 (50.0) | 1.00 | ... | 1.00 | ... |
| Yes | 124 | 17 (13.7) | .35 (.15–.81) | <.001 | .29 (.11–.74) | .010 |
| SAEs | | | | | | |
| None | 134 | 25 (18.7) | 1.00 | ... | ... | ... |
| Any SAE | 25 | 14 (56.0) | 5.08 (2.42–10.66) | <.001 | 4.81 (2.04–11.30) | <.001 |

Abbreviations: AFB, acid-fast bacilli; CI, confidence interval; DOT, directly observed therapy; HIV, human immunodeficiency virus; HR, hazard ratio; MDR, multidrug resistant; SAE, serious adverse event; TB, tuberculosis.
as stakeholders in LMICs; (3) the identification of those NTP challenges requiring immediate attention (eg, timely SLD procurement; TB/HIV testing/treatment services integration); and (4) suggestions of areas for future intervention research and/or implementation science.

Our study also has several limitations: (1) the retrospective, cohort study design is subject to unmeasured confounding factors that were not adjusted for and to the possibility of recall bias or data capture errors, leading to the misclassification of information on prior TB episodes/treatment; (2) extended genotypic DST of other key first-line drugs or SLDs was not routinely affordable/available in this setting; (3) a limited number of RR-TB patients were treated with the 9-month MDR-TB treatment regimen; and (4) the unknown HIV status of 18.8% of RR-TB patients, due to the unavailability of HIV test kits. Despite these shortcomings, our study provides important, new, and significant findings about RR-TB epidemiology and treatment outcomes in a challenging setting.

CONCLUSIONS

RR-TB was present in 11.1% of patients with confirmed TB in post-conflict DRC and was more frequent among patients with a positive sputum smear and retreatment TB. More than 45% of those with RR-TB had no prior TB episode, which highlights an urgent need for novel and effective household MDR-TB prevention strategies. Finally, we demonstrate that successful MDR-TB treatment is achievable in approximately 80% of patients in this setting. Scaling up the use of Xpert; the timelier initiation of shorter, safer, highly potent MDR-TB regimens; and consistent treatment adherence support are needed to optimize treatment outcomes.

Notes

Author contributions. A. N. H. B. assisted with the protocol development, data extraction, data analysis, interpretation of results, and drafting of the manuscript. J. A. N., J. C., and A. H. D. assisted with the data analysis, writing of the manuscript, data interpretation, and revisions. J. B. N. assisted with the protocol development, statistical analyses, interpretation of

Figure 4. Kaplan–Meier plots showing time to death or failure, stratified by: (A) DOT status; (B) grade III-IV SAEs; (C) HIV status (negative vs positive vs unknown); (D) by 9- vs 20/24-month MDR-TB regimens. Abbreviations: DOT, directly observed therapy; HIV, human immunodeficiency virus; MDR, multidrug resistant; RR, rifampicin resistant; SAE, serious adverse event; TB, tuberculosis.
results, writing of the manuscript, and revisions. R. M. helped with the data analysis, drafting of the manuscript, and revisions. Z. M. K. advised on the clinical and programmatic aspects of the manuscript. All authors reviewed the paper for additional interpretation, editing, and revisions and approved the final version.

Acknowledgments. The authors thank John L. Johnson, Case Western Reserve University; Sarita N. Shah, US Centers for Disease Control and Prevention; Serena P. Koenig, Brigham and Women's Hospital and Harvard Medical School; Kelly E. Dooley, Divisions of Clinical Pharmacology and Infectious Diseases, Johns Hopkins University; Gerald Friedland, Yale University; Helen Cox, University of Cape Town; Mark Nicol, Division of Medical Microbiology, University of Cape Town; Emmanuel André, Medical Microbiology, Université Catholique de Louvain, Brussels, Belgium; and Angelika Dramowski, and H. Simon Schaaf, Stellenbosch University Faculty of Medicine and Health Sciences, Cape Town, South Africa for their critical review of the manuscript. We also express our sincere gratitude to Ms. Caroline E. Connor for editing services, and the laboratory staff of the National Tuberculosis Program, Provincial Leprosy and Tuberculosis Coordination, South Kivu Branch, Bukavu, Democratic Republic of the Congo, who performed Xpert MTB/RIF tests: Rosette L. Nyota, Tengeneza Mayongwa, Andale Kale, Jean-Paul Muhanano, Sylvestre Ndariba, and Valery Badesire; as well as the dedicated field workers involved in data collection: Deo Muzigo and Aloise Fataki.

Financial support. Xpert MTB/RIF testing infrastructure was funded by Global Affairs Canada through STOP TB Partnership, TB REACH Wave-2 grant to the South Kivu Branch of Democratic Republic of the Congo (DRC) National Tuberculosis Program in 2011 (coordinates: Dr. Emmanuel André and Dr. Dieudonné Kahumuna). The GenoType MTBDRsl assays were funded by Vlaamse Interuniversitaire Raad - Universitaire Ontwikkelingsaanworsten (VLIR-UOS) Institutional University Cooperation (IUC) supplemental grant number PRDC 2012MP80. This IUC grant supports a partnership between Ghent University, the University of Antwerp, Katholieke Universiteit Leuven in Belgium, and the Université Catholique de Bukavu in the DRC (coordinates: Professor Kanigula Mubgwa and Professor Wenceslas Ruhana Mirindi Busane).

Potential conflicts of interest. J. B. N. is supported by research grants from the US National Institutes of Health (NIH)/National Institutes for Allergy and Infectious Disease, the AIDS Clinical Trial Group/Stellenbosch University Clinical Trial Unit (grant number 2UM1AI089521-08), and the Pittsburgh-Stellenbosch University AIDS-Comorbidities Training Research Program (NIH/Fogarty International Center; grant number 1D43TW010340-01). G.T and R.M.W are partially funded by the South African government through the South African Medical Research Council. A. H. D. is supported by the National Research Foundation of South Africa. Z. M. K. and B. C. B. are supported by Universitaire Ontwikkelingsaanworsten (VLIR-UOS) (grant number PRDC 2012MP80). All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1. Nachega JB, Chaisson RE. Tuberculosis drug resistance: a global threat. Clin Infect Dis 2003; 36:524–30.
2. World Health Organization. Global tuberculosis report 2018. Geneva, Switzerland: World Health Organization, 2018. Available at: http://apps.who.int/iris/bitstream/handle/10665/259366/9789241565516-eng.pdf;jsessionid=9B5AB-5925272079D4E42B715095E006888sequence=1. Accessed 29 August 2018.
3. Kaswa MK, Bisuta S, Kabuya G, Lunguya O, Ndongsengue O, Mayembe JI, Van Deun A, et al. Multi drug-resistant tuberculosis in Mosango, a rural area in the Democratic Republic of Congo. PLoS One 2014; 9(4):e89468.
4. Shanks L, Masumbuko EW, Ngoy NM, Maneno M, Bartlett S, Thi SS, Shah T. Treatment of multidrug-resistant tuberculosis in a remote, conflict-affected area of the Democratic Republic of Congo. Int J Tuberc Lung Dis 2012; 16(8):1066–8.
5. Council of Foreign Relations. Global conflict tracker: violence in the Democratic Republic of Congo. Available at: https://www.cfr.org/interactive/global-conflict-tracker/#/conflict/violence-in-the-democratic-republic-of-congo. Accessed 10 September 2018.
6. Boehme CC, Nabetta P, Hillemann D, Nicol MP, Shenai S, Krapf F, Allen J, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363(11):1005–15.
7. Armand S, Vanbuls P, Delcroix G, Courcol R, Lemaitre N. Comparison of the Xpert MTB/RIF test with an IS6110-TaqMan real-time PCR assay for direct detection of Mycobacterium tuberculosis in respiratory and nonrespiratory specimens. J Clin Microbiol 2011; 49:1772–6.
8. Boehme CC, Nicol MP, Nabetta P, Michael JS, Gotuzzo E, Taharl R, Glor MT, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377(9776):1495–505.
9. World Health Organization. WHO TB REACH programme. Geneva, Switzerland: World Health Organization, 2018. Available at: http://www.stoptb.org/global/awards/breach. Accessed 29 August 2018.
10. Creswell J, Codlin AJ, Andre E, Micek MA, Bedru A, Carter EJ, Yadav RP, et al. Results from early programmatic implementation of Xpert MTB/RIF testing in nine countries. BMC Infect Dis 2014; 14:2. PMID: 24383553. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898850/pdf/1471-2334-14-2.pdf.
11. Mbonze NB, Tabala M, Wenzel LK, Bakoko B, Brouwer M, Creswell J, Van Rie A, et al. Xpert(®) MTB/RIF for smear-negative presumptive TB: impact on case notification in DR Congo. Int J Tuberc Lung Dis 2016; 20(2):240–6.
12. Ministry of Health. National tuberculosis programme. Tuberculosis management. PATI-V: Democratic Republic of Congo, Kinshasa: Ministry of Health, 2018. Available at: https://www.medinbox.org/drc-guidelines-hiv-tb/guide-de prise-en-charge-de-la-tuberculose-pati-5/preview? Accessed 11 September 2018.
13. World Health Organization. Frequently asked questions about the implementation of the new WHO recommendation on the use of the shorter MDR-TB regimen under programmatic conditions. Geneva, Switzerland: World Health Organization, 2016. Available at: http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/FAQshorter_MDR_regimen.pdf?ua=1 Accessed 21 November 2018.
14. World Health Organization. Definitions and reporting framework for tuberculosis – 2013 revision. Geneva, Switzerland: World Health Organization, 2014. Available at: http://apps.who.int/iris/bitstream/10665/79199/1/9789241550345_eng.pdf Accessed 29 August 2018.
15. Gagneux S, Long CD, Small PM, Van T, Schoolnik GK, Bohannan BJ. The competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science 2006; 312:1944–6.
16. Ragonnet R, Trauer JM, Denholm JT, Marais B, McEvoy ES. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from? BMC Infect Dis 2017; 17:36. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5231796/pdf/12879_2016_Article_2171.pdf.
17. Schreiber YS, Herrera AJ, Wilson D, Wallengren K, Draper R, Muller J, Dawood H, et al. Tuberculosis treatment category predicts resistance in hospitalized treatment patients in a high HIV prevalence area. Int J Tuberc Lung Dis 2009; 13(10):1274–80.
18. Seddon JA, Warren RM, Enarson DA, Beyers N, Schaaf HS. Drug-resistant tuberculosis treatment and resistance amplification within families. Emerg Infect Dis 2012; 18:1342–5.
19. Workicho A, Kassahun W, Alemseged F. Risk factors for multidrug-resistant tuberculosis among tuberculosis patients: a case-control study. Infect Dis 2017; 10:91–6.
20. Kendall EA, Fofana MO, Dowdy DW. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med 2015; 3:563–72.
21. Shah NS, Auld SC, Brust JC, Mathema B, Ismail N, Moodley P, Misiana K, et al. Transmission of Extensively Drug-resistant Tuberculosis in South Africa. N Engl Med 2017; 376(3):243–53.
22. Dowdy DW, Theron G, Tornheim JA, Warren R, Kendall EA. Of testing and treatment: implications of implementing new regimens for multidrug-resistant tuberculosis. Clin Infect Dis 2017; 65:1206–11.
23. Suchindran D, Brouwer ES, Van Rie A. Is HIV infection a risk factor for multidrug resistant tuberculosis? A systematic review. PLoS One 2009; 4:e5561.
24. Mesfin YM, Hailemariam D, Biadglegn S, Biadglegn S, Kibret KT. Association between HIV/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysis. PLOS One 2014; 9:e82235.
25. van den Hof S, Tursynbayeva A, Abidilova T, Adenov M, Pak S, Bekembayeva G, Ismailov S. Converging risk factors but no association between HIV infection and multidrug-resistant tuberculosis in Kazakhstan. Int J Tuberc Lung Dis 2013; 17(4):526–31.
26. Isakidis P, Casas EC, Das M, Tsiretopoulou X, Ntzani EE, Ford N. Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. Int J Tuberc Lung Dis 2015; 19:699–78.
27. Ahmad Khan F, Salim MAH, du Clos P, Casas EC, Khamraev A, Sikhozane W, Benedetti A, et al. Effectiveness and safety of standardised shorter regimens.
for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses. Eur Respir J 2017; 50(1): p1: 1700061. Available at: https://erj.ers-journals.com/content/erj/50/1/1700061.full.pdf

28. Aung KJ, Van Deun A, Declercq E, Sarker MR, Das PK, Hossain MA, Rieder HL. Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patients. Int J Tuberc Lung Dis 2014; 18(10):1180–7.

29. Kuaban C, Noeske J, Rieder HL, Ait-Khaled N, Abena Foe JI, Trébucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis 2015; 19:517–24.

30. Piubello A, Harouna SH, Souleymane MB, Boukary I, Morou S, Daouda M, Hanki Y, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis 2014; 18(10):1188–94.

31. Trébucq A, Schwobel V, Kashongwe Z, Bakayoko A, Kuaban C, Noeske J, Hassane S, et al. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries. Int J Tuberc Lung Dis 2018; 22(1):17–25.

32. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010; 182(5):684–92.

33. Moodley R, Godec TR; STREAM Trial Team. Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Respir Rev 2016; 25:29–35.

34. World Health Organization. Position statement on the continued use of the shorter MDR-TB regimen following an expedited review of the STREAM Stage I preliminary results. Geneva, Switzerland: World Health Organization, 2018. Available at: http://www.who.int/tb/areas-of-work/drug-resistant-tb/treatment/WHOPositionStatementShorterRegimensSTREAMStageI.pdf?ua=1. Accessed 13 August 2018.

35. World Health Organization. Rapid communication: key changes to treatment of multidrug- and rifampcin-resistant tuberculosis (MDR/RR-TB). Geneva, Switzerland: World Health Organization, 2018. Available at: http://www.who.int/tb/publications/2018/WHO_RapidCommunicationMDRTB.pdf?ua=1. Accessed 21 November 2018.

36. Dheda K, Cox H, Esmail A, Wassail S, Chang KC, Lange C. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? Respiratology 2018; 23:36–45.

37. Diaco AH, Pym A, Grobusch MP, de los Rios JM, Gotuzzo E, Vasilyeva I, Leimane V, et al. TMC207-C208 Study Group. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med 2015; 371(8):723–32.

38. Gler MT, Skripconoka V, Sanchez-Garavito E, Xiao H, Cabrera-Rivero JL, Vargas-Vasquez DE, Gao M, et al. Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366(23):2151–60.

39. Cox V, Brigden G, Crespo RH, Lessem S, Lynch S, Rich ML, Waning B, et al. Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2018; 22(4):407–12.

40. Ahuja SD, Ashkin D, Avendano M, Banerjee R, Bauer M, Bayona JN, Becerra MC, et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med 2012; 9(8):e1001300.

41. Charles M, Vilbrun SC, Koenig SP, Hashiguchi LM, Mabou MM, Ocheretina O, Pape JW. Treatment outcomes for patients with multidrug-resistant tuberculosis in post-earthquake Port-au-Prince, Haiti. Am J Trop Med Hyg 2014; 91(4):715–21.

42. Richterman A, Steer-Massaro J, Jarolimova J, Luong Nguyen LB, Werdenberg J, Ivers LC. Cash interventions to improve clinical outcomes for pulmonary tuberculosis: systematic review and meta-analysis. Bull World Health Organ 2018; 96:471–83.